{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:24:27Z","timestamp":1794014667726,"version":"4.8.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immunoglobulin A (IgA) is mostly considered as a non-inflammatory regulator at mucosal areas. However, previous work of our group showed that IgA can also be involved in disease pathology, because it provides a potent stimulus to activate neutrophils after crosslinking of surface CD89 (FcaRI), resulting in chronic inflammation and tissue damage. IgA (auto)antibodies and neutrophils are key players in various diseases, including blistering skin diseases and rheumatoid arthritis. Therefore, we generated an array of anti-CD89 monoclonal antibodies (mAbs) for therapeutic targeting of CD89. The biological activity of newly developed anti-human CD89 mAbs and their potential therapeutic capacity were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Human neutrophils were isolated from heparinized healthy donor blood. The ability of anti-CD89 mAbs to bind human neutrophils was investigated by flow cytometry. Furthermore, the capacity of these anti-CD89 mAbs to inhibit IgA-mediated phagocytosis, neutrophil extracellular trap (NET) release and migration was studied. To this end, neutrophils were pre-incubated with\/without anti-CD89 mAbs after which they were stimulated with IgA-coated beads. The amount of phagocytosed beads, NET release and migrated neutrophils were subsequently analysed. In parallel, chemoattractant leukotriene B4 and lactoferrin (as a measure for degranulation) release were determined. Finally, the therapeutic potential of our prototypic anti-CD89 mAb clone 10E7 was in vivo tested in anti-mouse collagen XVII human IgA-treated transgenic CD89 mice, a preclinical model for autoimmune linear IgA bullous disease (LABD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results show that all generated anti-CD89 mAbs bound surface CD89 on neutrophils. Although these anti-CD89 mAbs bind to different epitopes on EC1 of CD89, they all have the capacity  to inhibit IgA-mediated phagocytosis, neutrophil extracellular trap (NET) release and neutrophil  migration. Moreover, IgA mediated leukotriene B4 and lactoferrin release are decreased in supernatant from anti-CD89 mAbs-treated neutrophils. Finally, anti-CD89 mAb clone 10E7, that was selected based on its selective binding profile on tissue micro arrays, reduced anti-mouse collagen XVII hIgA-induced neutrophil influx in an in vivo linear IgA bullous disease (LABD) mice model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study clearly indicates that our newly developed anti-CD89 mAbs inhibited IgA-induced neutrophil activation and reduced anti-autoantigen IgA-induced neutrophil influx in vivo, supporting further clinical development for the treatment of LABD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1118539","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T06:58:48Z","timestamp":1680591528000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Antagonizing Fc\u03b1R1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity"],"prefix":"10.3389","volume":"14","author":[{"given":"Myrthe A. M.","family":"van Delft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esil","family":"Aleyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard van der","family":"Mast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van Egmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00553","article-title":"IgA and FcalphaRI: Pathological roles and therapeutic opportunities","volume":"10","author":"Breedveld","year":"2019","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41385-019-0227-4","article-title":"IgA and the intestinal microbiota: The importance of being specific","volume":"13","author":"Pabst","year":"2020","journal-title":"Mucosal Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4614-7107-3_2","article-title":"Immunoglobulin a: Molecular mechanisms of function and role in immune defence","author":"Woof","year":"2013","journal-title":"Mol Cell Mech Antibody Activity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/path.1877","article-title":"The function of immunoglobulin a in immunity","volume":"208","author":"Woof","year":"2006","journal-title":"J Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S266242","article-title":"IgA and Fc\u03b1RI: Versatile players in homeostasis, infection, and autoimmunity","volume":"9","author":"van Gool","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300261","article-title":"IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via fcalpha receptor I","volume":"192","author":"Aleyd","year":"2014","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1053\/j.gastro.2009.06.047","article-title":"Immunoglobulin a: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4","volume":"137","author":"van der Steen","year":"2009","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41467-018-03318-5","article-title":"FcalphaRI co-stimulation converts human intestinal CD103(+) dendritic cells into pro-inflammatory cells through glycolytic reprogramming","volume":"9","author":"Hansen","year":"2018","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651049","article-title":"IgA immune complexes induce osteoclast-mediated bone resorption","volume":"12","author":"Breedveld","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.smim.2021.101581","article-title":"Therapeutic exploitation of neutrophils to fight cancer","volume":"57","author":"Gruijs","year":"2021","journal-title":"Semin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/76261","article-title":"FcalphaRI-positive liver kupffer cells: Reappraisal of the function of immunoglobulin a in immunity","volume":"6","author":"van Egmond","year":"2000","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.171.3.597","article-title":"Cellular distribution, regulation, and biochemical nature of an fc alpha receptor in humans","volume":"171","author":"Monteiro","year":"1990","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/332647a0","article-title":"GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA fc receptor activation mechanism","volume":"332","author":"Weisbart","year":"1988","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2021","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101763","article-title":"Blocking fcalpha receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies","volume":"189","author":"van der Steen","year":"2012","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2005.00367.x","article-title":"Mechanisms of blister induction by autoantibodies","volume":"14","author":"Sitaru","year":"2005","journal-title":"Exp Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.732977","article-title":"Anti-Fc\u03b1RI monoclonal antibodies resolve IgA autoantibody-mediated disease","volume":"13","author":"Bos","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"914162","DOI":"10.1155\/2012\/914162","article-title":"Recent advances in dermatitis herpetiformis","volume":"2012","author":"Nakajima","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"AnnRheumDis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102392","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","author":"van Delft","year":"2020","journal-title":"J Autoimmun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.15","article-title":"Beyond citrullination: Other post-translational protein modifications in rheumatoid arthritis","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B24","article-title":"The association of immunoglobulin a, immunoglobulin G and anti-cyclic citrullinated peptide antibodies with disease activity in seronegative rheumatoid arthritis patients","volume":"19","author":"Karimifar","year":"2014","journal-title":"JResMedSci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1398.034","article-title":"Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients","volume":"1109","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann New York Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060608","article-title":"High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis","volume":"66","author":"Bobbio-Pallavicini","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041376","article-title":"Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset","volume":"65","author":"Berglin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402334","article-title":"IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies","volume":"194","author":"Anquetil","year":"2015","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B29","doi-asserted-by":"publisher","first-page":":161","DOI":"10.3390\/cells7100161","article-title":"Pathogenic role of immune cells in rheumatoid arthritis: Implications in clinical treatment and biomarker development","volume":"7","author":"Yap","year":"2018","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.06.006","article-title":"Neutrophils: Novel key players in rheumatoid arthritis. current and future therapeutic targets","volume":"17","author":"Cecchi","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502353","article-title":"IgA complexes in plasma and synovial fluid of patients with rheumatoid arthritis induce neutrophil extracellular traps via FcalphaRI","volume":"197","author":"Aleyd","year":"2016","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.12.4387","article-title":"Human immunoglobulin a receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b\/CD18)","volume":"93","author":"van Egmond","year":"1999","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912393107","article-title":"Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation","volume":"107","author":"Duchez","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1534","article-title":"Identification of a novel class of mammalian fc gamma receptor","volume":"155","author":"Zhang","year":"1995","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2419","article-title":"Pentraxins and IgA share a binding hot-spot on Fc\u03b1RI","volume":"23","author":"Lu","year":"2014","journal-title":"Protein Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.11.1715","article-title":"Immunoglobulin-binding sites of human FcalphaRI (CD89) and bovine Fcgamma2R are located in their membrane-distal extracellular domains","volume":"189","author":"Morton","year":"1999","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01949.x","article-title":"Identification and characterization of macaque CD89 (immunoglobulin a fc receptor)","volume":"113","author":"Rogers","year":"2004","journal-title":"Immunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.iac.2012.04.011","article-title":"Dapsone in the management of autoimmune bullous diseases","volume":"32","author":"Piette","year":"2012","journal-title":"Immunol Allergy Clinics North America"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(00)00185-1","article-title":"Linear IgA bullous dermatosis","volume":"19","author":"Guide","year":"2001","journal-title":"Clinics Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01321.x","article-title":"Localized linear IgA disease responding to colchicine","volume":"41","author":"Benbenisty","year":"2002","journal-title":"Int J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0738-081x(91)90031-f","article-title":"Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood)","volume":"9","author":"Jab\u0142o\u0144ska","year":"1991","journal-title":"Clinics Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12443","article-title":"IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis","volume":"17","author":"Sakthiswary","year":"2014","journal-title":"IntJRheumDis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1118539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T06:58:52Z","timestamp":1680591532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1118539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2023.1118539"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1118539","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"1118539"}}